RPG LIFE SCIENCES LIMITED
Regd. Off.: RPG House
463, Dr. Annie Besant Road
Worli, Mumbai 400030, India
Tel: +91-22-24981650 / 66606375
Fax: +91-22-24970127
Email: info@rpglifesciences.com
www.rpglifesciences.com
CIN : L24232MH2007PLC169354

July 28, 2026

To,

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

Symbol: RPGLIFE

BSE Limited
Corporate Relationship Department
Floor 25, P.J. Towers
Dalal Street
Mumbai 400 001.

Scrip code: 532983

Dear Sir/Madam,

Sub: Investor Presentation - Financial Results

Please find enclosed herewith a copy of Investor Presentation with respect to Unaudited Financial Results of the Company for the quarter ended June 30, 2026.

Kindly take the above on record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited

RAJESH RAMESH SHIRAMBEKAR
Digitally signed by RAJESH RAMESH SHIRAMBEKAR
Date: 2026.07.28 20:36:14 +05'30'

Rajesh Shirambekar
Head – Legal & Company Secretary

Encl: as above

Q1 FY27 Performance

RPG Life Sciences

Investors’ Presentation
July 2026

Disclaimer

This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements.

The company operates in the Pharmaceutical segment. Some of the historical Profit and loss numbers which are sliced in the investor presentation for certain sales divisions are purely for broader understanding for investors of the business of the company and its growth trajectory. The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoter or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this document or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. The information and opinions contained in this presentation are current, and if not stated otherwise, as of the date of this presentation. The Company undertake no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice.

This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of RPG Life Sciences Limited Limited (the “Company”), nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment, therefore. Any person/ party intending to provide finance / invest in the shares/businesses of the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. This presentation is strictly confidential and may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations.

RPG Group: Powered by Passion, Driven by Ethics

UNLEASH**TALENT**
TOUCH**LIVES**
OUT**PERFORM**
AND☺

RPG Enterprises was founded in 1979. The group currently operates various businesses in Infrastructure, Technology, Life Sciences, Plantations and Tyre industries. The group has business history dating back to 1820 AD in banking, textiles, jute and tea. The Group grew in size and strength with several acquisitions in the 1980s and 1990s. RPG Group is one of India's fastest growing conglomerates with 31,000+ employees, presence in 135+ countries and annual gross revenues of USD 5.2 Bn

KEC	CEAT	zensar	RPG LIFE SCIENCES	Raychem RPG	HARRISONS MALAYALAM LIMITED
EPC major in infrastructure segments like T&D, Civil, Transportation, Oil & Gas, Renewables & Cables	One of India's leading tyre manufacturers	Global technology consulting and IT services company	Integrated pharma company in formulations and synthetic APIs	Technology solutions company catering to energy and infrastructure	One of India's largest plantation companies producing tea, rubber, etc.

RPG Life Sciences: An Integrated Pharmaceutical Company

RPG Life Sciences is an integrated research based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space.



Domestic Formulations (DF)
Develop, manufacture and market branded formulations in India & Nepal

International Formulations (IF)
Develop, manufacture and market oral solid dosage formulations in the generics and branded generics space

APIs
Develop, manufacture and sell high value synthetic APIs in the general therapeutic category

Leader in Immunosuppressants

9 Therapies represented by High Equity Brands

50+ Markets Presence

Manufacturing Facilities – API and Formulations

1445+ Employees

RPG Life Sciences: Strong Product Portfolio, Textbook brands; focus on chronic & specialty therapies

Key Therapies

- Nephrology
- Rheumatology
- Oncology
- Pain Management
- Gastroenterology
- Neuropsychiatry
- Cardio- Diabeto
- Urology

DF Key Products

Legacy Portfolio

Immunosuppressants

- Azoran – Azathioprine
- Mofetyl – Mycophenolate Mofetil
- Arpimune ME – Cyclosporine
- Imunotac – Tacrolimus

Textbook Brands

- Azoran – Azathioprine
- Aldactone – Spironolactone
- Lomotil – Diphenoxylate HCl
- Naprosyn – Naproxen
- Serenace – Haloperidol
- Norpace New – Disopyramide Phosphate

New Portfolio

Specialty

- HerMab – Trastuzumab
- Adlumab – Adalimumab
- Ivzumab – Bevacizumab
- Zestmab – Rituximab
- T-JAKI – Tofacitinib
- FC-IRO – Ferric Carboxymaltose
- Denbri – Denosumab

Chronic

- SacuNew – Sacubitril+ Valsartan
- NuGliptin – Vildagliptin
- GliptiNext – Teneligliptin
- DPO 10 – Dapagliflozin
- Solifirst – Solifenacin
- Mirasmart S – More Smart.. More Efficient

Life Cycle Management (Existing Products)

- Azoran 75
- Aldactone T
- Aldactone F
- Naprosyn +
- Naprosyn + Gel – The Pain-Relief Expert
- Naprosyn M
- ROMILAST-BL
- Tricaine Alma

IF Key Products

Generics - Azathioprine, Sodium Valproate PR, Nicorandil, Sertraline and so on

Branded Generics – Siloxogene, Azoran, Mofetyl, Arpimune ME, Dyzantil, Dipsope and so on

APIs Key Products

Quinfamide, Azathioprine, Haloperidol, Risperidone, Propantheline Bromide, Nicorandil, Pantoprazole and so on

Business Operations

Quality – Centric Operations with Scalable Capabilities

Formulation - Ankleshwar, Gujarat

- Located in the industrial town of Ankleshwar in Gujarat, India; the Multipurpose plant with dedicated product lines for Oral Dosage forms including tablets, liquids, and powder. This manufacturing facility is equipped to handle products which require very low humidity during processing and caters to the regulated markets. The unit has a strong production capacity and caters to the Domestic and Emerging markets.

API - Navi Mumbai, Maharashtra

- The API Manufacturing facility consists of three district units, each aligned to specific market requirements. MF2 operates as a dedicated immunosuppressant unit, while MF3 and MF4 are multipurpose facilities, collectively catering to regulated markets.

Digital Initiatives: Manufacturing and Quality

Digital Retina Scanner

- Biometric Access with IRIS/ Retina Scanner enables consistency of electronic records and signatures
- Access to only qualified professionals, Batch Management, Recipe Management, Audit logs

Intelligent Chilling Plant Manager

- Implementation of Utility Asset Management Systems with access over IoT, supported by Customized Algorithms for Efficient Monitoring, Control & Analytics

IOT based AHU monitoring system

- Operates Pumps & Chillers according to Operating Hours to maintain equal run time
- Automatically change over Working pump to Standby if Pump fails during operation

Power Management System

- Safe, reliable, efficient, and compliant operation of electrical distribution systems, and connected assets always enabled

Quality Functions

e-QMS: Digital platform to track all 6 quality parameters

e-DMS: Digital platform to manage manufacturing/quality documents

e-LMS: Digital platform to track training sessions on CGMP

Focusing on execution to drive growth & efficiency

Driving improvement across cost, quality, growth & productivity

1

Strengthening Manufacturing & Capacity

Enhancing capacity and capabilities to support scalable and future-ready growth

2

Driving Cost Efficiency

Implementing cost optimization initiatives to improve productivity and operating margins

3

Enhancing Quality & Compliance

Strengthening quality systems and compliance to ensure consistent reliability

4

Accelerating New Products & Innovation

Investing in R&D and innovation to drive new launches and specialty expansion

5

Leveraging Digital & Productivity

Using digital initiatives to enhance execution, reach and overall productivity

6

Expanding Global Presence

Strengthening our footprint and partnerships to unlock opportunities in fast-growing global markets

Multiple initiatives underway with defined KPIs and strong review mechanisms

Business Strategy

Key strategic priorities for our business

1. Driving a more purpose-led and performance-oriented organization with stronger alignment across teams
2. Scaling core brands with sustained double-digit growth like Naprosyn progressing towards becoming a ₹100 cr+ brand
3. Building a stronger specialty and chronic portfolio with increasing contribution from new launches
4. Strengthening the API business with improved operational resilience and recovery post disruption
5. Expanding global presence with focused investments and deeper engagement with key international customers
6. Embedding cost discipline and ESG-led practices to drive long-term sustainable operations

Domestic Formulations (DF) Business: Overview & Strategy

Business Overview

Leading Textbook Brands
Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace

Diverse Portfolio
Operating across mass, mass-specialty, and specialty segments.

Innovation & Growth
New launches in biosimilars, chronic, and specialty segments.

Specialist Reach
Strong presence across key specialties (Cardio, Diabetes, Urology, Nephrology, Rheumatology, Oncology)

Strategy

5 pillars of profitable domestic business growth

1. **Product Portfolio Rejuvenation:** Building chronic and specialty portfolios with new launches
2. **Strategic Brand Asset Building:** Life cycle management through new line extensions, customer segments, & disease segments.
3. **Customer Coverage Deepening:** Expanding field force & deploying digital solutions in targeted therapies
4. **Sales Force Effectiveness Augmentation:** Enhancing competencies and productivity through targeted initiatives.
5. **Profitability Improvement:** Controlling costs, improving efficiency, strengthening sales discipline, and focusing on profitable mix.

International Formulations (IF) Business: Overview & Strategy

Business Overview

Global Reach
Presence in regulated and emerging markets across Canada, UK, Germany, France, Australia, SE Asia, and Africa

Specialist Leadership
Strong position in immunosuppressants, with Azathioprine as a flagship product.

Trusted Partnerships
Impeccable supply track record and enduring relationships with leading global generic players.

Quality & Expansion
Preferred partner for high-quality, process-oriented manufacturing; ongoing investments in plant upgrades and capacity expansion.

Strategy

3 pillars of step-wise global business build up

1

Build Immunosuppressant Portfolio:
Expand leadership in immunosuppressants, anchored by flagship products like Azathioprine.

2

Focus on Products with Competitive Advantage:
Prioritize products requiring special manufacturing conditions (e.g., low RH/temperature), complex generics, and those with low competition

3

Expand Footprint in Emerging and Select Markets:
Grow presence in markets such as Myanmar, Vietnam, Philippines, Sri Lanka, Egypt, Sudan, Thailand, and South Africa.

APIs Business: Overview & Strategy

Business Overview

Niche API Focus
High-value, low-volume APIs and mature, stable molecules.

Global Presence
Presence across key geographies: LATAM, Germany, China, South Korea, Iran, Bangladesh, Egypt, India, and more.

Strategic Integration
Backward integration with International Formulations, strengthening supply chain resilience.

Trusted Partnerships
Enduring relationships with major pharma and leading generic companies.

Strategy

3 pillars of API growth

1

Market & Customer Expansion:
Grow reach for existing products in new and established markets.

2

Niche Product Pipeline:
Develop immunosuppressants, limited competition products, and support backward integration for IF/DF.

3

State-of-the-Art Manufacturing:
Operate EU/TGA-approved plant with enhanced capacity for quality and compliance.

Q1- FY27 Performanc

Robust Q1- 27 performance with 15.8% revenue growth and 17.0% PAT growth

15.8%

Revenue from operations

Q1 FY27 v/s Q1 FY26

17.9%

EBITDA

Q1 FY27 v/s Q1 FY26

17.0%

PAT (excl. exceptional items)

Q1 FY27 v/s Q1 FY26

Q1 FY27 Financial Performance (Consolidated) : Revenue up by 15.8% with improved profitability

(All values in Rs. Crores)

values in circle are margins

Revenue from Operations



EBITDA & EBITDA Margin



PBT & PBT Margin



PAT & PAT Margin



Q1 FY27: Business Segment-wise Performance Update

All sales value in INR cr.

Domestic Formulations (DF)

Domestic Formulations contributed 68.3% to total sales in Q1 FY27

- Continue to deliver market beating growth
- New products contribution improving consistently on account of new launches in specialty & chronic segments
- Salesforce productivity consistently improving (currently >6.5 lakhs)
- Business driven by 5 Pillar strategy



International Formulations (IF)

International Formulations contributed 18.0% to total sales in Q1 FY27

- Focus on long-term business development activities including adding new products, customers and markets
- Business driven by e Pillar strategy



API

API contributed 13.7% to total sales in Q1 FY27

- Growth impacted due to fire incident in one of the manufacturing blocks
- Continuous thrust on new customer development
- Business driven by 3 Pillar strategy



RPG Life Sciences ICRA Rating Reaffirmation: A+ rating continues

Improvements recorded in ICRA Rating- June'26

Long term rating reaffirmed at **A+** and outlook retained as stable

Short term rating reaffirmed at **A1**

Factors contributing rating affirmation

- A robust capital structure and strong debt servicing indicators based on:
  - Healthy cash flows
  - Strong balance sheet
  - No debt-funded capital expenditure (capex)
- Steady growth in top-line and improving operating margins
- Strong brands in the Indian Pharmaceutical Industry
- Expansion of product portfolio and geographical presence augur well for growth prospects

Key milestones in Q1 FY27

RPGLS enters coveted list of "Top 50 Pharma Company" in June'26

Key highlights

1 RPGLS has **advanced IPM[2] ranking from Rank 62 in Mar'25 to Rank 50 in June'26[2]**

2 Among the **Top 5 Fastest Growing Companies in IPM[1]** in Q1 FY27

1. Indian pharma market 2. Source: Pharmarack MAT June 2026 Database

Our efforts gaining external recognition; 3 industry awards received in Q1 FY27

Awarded the prestigious "Top Nephrology Company-2026"

Awarded for delivering strong patient care through robust portfolio of high-quality medicines in kidney care space

Awarded for "Best Use of AI in Sales Force Effectiveness"

Gaining traction of select SFE and AI platforms built in FY26

Awarded for "Excellence in Breakthrough Pharmaceutical Innovations"

Awarded for deploying innovative sales force effectiveness measures like automation of secondary sales statements and league table scorecard for the field

Journey Ahead

RPGLS Journey Ahead: 7 strategic pillars of action

1	**Portfolio development and mega-brands building**	• Project underway to grow our immunosuppressant portfolio to 200+ crores • Focused initiatives to grow Naprosyn to a 100+ crores brand; building our MABs portfolio
2	**Growing our API business**	• Focus on new geographies, new launch pipeline and enhancing manufacturing productivity • Focus on strengthening customer relationships and onboarding new high-value customers
3	**Strong Digital Roadmap**	• Multiple digital initiatives designed to streamline front-end and backend operations • Initiatives focus on improving efficiency & compliance, reducing costs and growing topline
4	**Mergers & Acquisitions**	• M&A Framework with criteria defined - target therapies, brands • Evaluation of multiple proposals underway to identify opportunities for growth synergy
5	**New products across segments, new therapies**	• Focused new product pipeline; lab modernization and org expansion complete • Strategy to evaluate and expand into adjacencies in RPGLS strength therapies
6	**State-of-art capacity plants**	• Rs 185+ crores capex infused since FY22 helped build modern plant with EU, TGA, PMDA, etc. approval • Evaluation ongoing of varied opportunities for improving manufacturing productivity
7	**Talent Transformation**	• Org structure review & role/skill-gaps identification for strengthening • Talent development and talent acquisition across all key business and support functions

THANK YOU

RPG LIFE SCIENCES